Publications

Oncologie

Camus V, Etancelin P, Drieux F, Veresezan EL et al. Complete hematologic response after belinostat treatment and allogeneic stem cell transplantation for multiple relapsed/refractory angioimmunoblastic T-cell lymphoma: a case report. Clin Case Report 2023; 11(6):e7623 (aide à la rédaction).

Filipits M, Kainz V, Sebek V, Zach H et al. Epidermal Growth Factor Receptor T790M Mutation Testing in Non-Small Cell Lung Cancer: An International Collaborative
Study to Assess Molecular EGFR T790M Testing inLiquid Biopsy. Cancers 2023; 15(13):3528 (aide à la rédaction).

Joly F, Lefevre L, Stitou H, Bombezin–Domino A. Patient perspectives on the daily burden of prostate cancer: an online patient study. JMIR 2023; epub ahead a print (aide à la rédaction).

Illini O, Fabikan H, Hochmair MJ, Weinlinger C et al. Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study. J Clin Med 2022; 11(14): 4098 (aide à la redaction).

Illini O, Fabikan H, Swalduz A, Vikström A et al. Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program. Ther Adv med Oncol 2022;14:17588359221103206 (aide à la rédaction).

Boulmé F. ASCO solid tumors congress report 2021/2022/2023, memo InOncology/PharmaNews Springer-Verlag GmbH (bit.ly/3fKeGRg).

Boulmé F. ESMO solid tumors congress report 2021/2022/2023, memo InOncology/PharmaNews Springer-Verlag GmbH (bit.ly/3IJhdYv).

Boulmé F. ESMO-IO solid tumors congress report 2021/2022, memo InOncology Springer-Verlag GmbH (bit.ly/3IJhdYv).

Boulmé F. ASH congress report 2020/2022, memo InHaematology Springer-Verlag GmbH.

Boulmé F. iwWM congress report 2022, memo InHaematology Springer-Verlag GmbH.

Hochmair MJ, Illini O, Prosch H, Krenbek D et al. Complete Remission to Afatinib in a Patient Harboring a Novel Epidermal Growth Factor Mutation in De Novo Small-Cell Lung Cancer: A Case Report. Clin Lung Cancer 2021; S1525-7304(21)00277-1 (aide à la rédaction).

Illini O, Hochmair MJ, Fabikan H, Weinlinger C et al. Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Ther Adv Med Oncol 2021; 13: 17588359211019675 (aide à la rédaction).

Boulmé F. RET comme cible thérapeutique dans les cancers du poumon et de la thyroide. SPECTRUM Onkologie e-news. Medahead, Juin 2021, en allemand (bit.ly/3w4txf0).

Boulmé F. RET comme driver oncogénique dans le cancer avancé de la thyroide. SPECTRUM Onkologie e-news. Medahead, Juin 2021, en allemand (bit.ly/3x7m5kq).

Boulmé F. FMC: La maladie des cellules falciformes. Die Punkte:On, MedMedia Austria, Mai 2021, en allemand.

Boulmé F. Selpercatinib chez des patients atteints d’un stage avancé de cancer du poumon (NSCLC) avec une fusion positive à RET. Rapport de cas (en allemand). MedMedia, Mars 2021. (https://www.medmedia.at/apps/download/download_pdf.php?file=wp-content/uploads/2021/03/2021_Eli_CasR_Selpercatinib.pdf).

Boulmé F. FMC: La nouvelle ère de l’immunothérapie dans le cancer: le rôle du médecin de famille. Die Punkte:On, Medizin Medien Austria, Mars 2021, en allemand. (https://www.medmedia.at/diepunkteon/neue-aera-immuntherapie-bei-krebs-rolle-praktische-aerzte/#/).

Hochmair MJ, Prosch H, Krenbek D, Weinlinger C et al. Alectinib following brigatinib: an efficient sequence for the treatment of advanced anaplastic lymphoma kinase-positive lung cancer patients. Anticancer Drugs 2021; 32(1): 105-110 (aide à la rédaction).

Boulmé F. FMC: “Real World Evidence”. CliniCum Onko, Medizin Medien Austria, septembre 2020, en allemand. (https://medonline.at/fortbildung/dfp-e-learning/clinicum-onko/10057611/real-world-evidence/).

Boulmé F. Prise de position: avons-nous besoin de changer la thérapie du RCC pendant l’épidemie de COVID-19? Meeting d’experts virtuel, RCC Academy, aout 2020, en allemand (https://cancercase.net/fileadmin/user_upload/ACADEMY_Events/Positionspapier_RCC_COVID19_Expertenmeeting.pdf).

Boulmé F. medonline: Onko News (articles en allemand). (2020). (https://medonline.at/autoren-und-experten/dr-florence-boulme/).

Boulmé F. FMC: Precision Oncology. CliniCum Onko, Medizin Medien Austria, avril 2020, en allemand. (https://medonline.at/fortbildung/dfp-e-learning/clinicum-onko/10054250/precision-oncology-el/).

Boulmé F. Cancer du poumon; première cause de décès. Ärzte Woche (9), Springer-Verlag, février 2020, en allemand.

Virologie

F. Boulmé. ECCMID 2023 congress report.

Bouwensch C, Hahn V, Boulmé F. Analysis of 160 nonhospitalized COVID-19 patients with mild to moderate symptoms from an Austrian general medical practice: from typical disease pattern to unexpected clinical features. Wiener Medizinische Wochenschrift 2022; 172(9-10): 198-210.

LaMori J, Seignez A, Radoszycki L. Patient Satisfaction with Once-Daily Single-Tablet Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (DRV/c/FTC/TAF): A Real-World Study of Patient Self-Reported Outcomes in HIV-1-Diagnosed Adults. Patient Prefer Adherence 2022; 16: 83-94 (aide à la rédaction).

Blakemore C., Hunter J., Basu B. Rapid swallow improvement following pharyngeal electrical stimulation in a COVID-19 patient with long-term severe neurogenic dysphagia: a case report. JRM-CC 2021; 4: 1000073 (aide à la rédaction).

Pécout C, Pain E, Chekroun M, Champeix C et al. Impact of the COVID-19 pandemic on patients affected by non-communicable diseases in Europe and in the USA. Int J Environ Res Public Health 2021; 18(13): 6697 (aide à la rédaction).

Traugott M, Hoepler W, Kitzberger R, Pavlata S et al. Successful treatment of intubation-induced severe neurogenic post-extubation dysphagia using pharyngeal electrical stimulation in a COVID-19 survivor: a case report. J Med Case Rep 2021; 15(1): 148 (aide à la rédaction).

Boulmé F. Recommandations pour le traitement en unité de soins intensifs des patients positifs au SARS-CoV-2. Ärzte Woche (17), Springer-Verlag, avril 2020, en allemand.

Boulmé F. FMC: SARS-CoV-2 dans la salle d’attente. Ärzte Woche (12), Springer-Verlag, mars 2020, en allemand. (https://www.springermedizin.at/infektiologie/innere-medizin/sars-cov-2-im-wartezimmer/17805496)

Freund F, Boulmé F, Litvak S, Tarrago-Litvak L. Initiation of HIV-2 reverse transcription: a secondary structure model of the RNA-tRNA(Lys3) duplex. Nucleic Acids Res 2001; 29, 2757-2765.

Freund F, Boulmé F, Michel J, Ventura M et al. Inhibition of HIV-1 replication in vitro and in human infected cells by modified antisense oligonucleotides targeting the tRNALys3/RNA initiation complex. Antisense Nucleic Acid Drug Dev 2001; 11, 301-15.

Litvak S, Andréola ML, Boulmé F, Freund et al. (2001) Reverse transcriptase of HIV-1: novel therapeutic interventions” in “Pharmacology of HIV infection and AIDS, edited by Dietmar Fuchs, OICA International Press, Saint-Lucia, London.

Boulmé F, Freund F, Gryaznov S, Nielsen PE et al. Study of HIV-2 primer-template initiation complex using antisense oligonucleotides. Eur J Biochem 2000; 267, 2803-2811.

Mestre B, Arzumanov A, Singh M, Boulmé F et al. Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA. Biochim Biophys Acta 1999; 1445, 86-98.

Boulmé F. In vitro effect of phosphodiester and chemically modified antisense oligonucleotides on the initiation step of the HIV-1 and HIV-2 reverse transcription. PhD obtained on the 22nd of June1998, University of Bordeaux II, France.

Boulmé F, F. Freund, S. Moreau, P. E. Nielsen, S. Gryaznov, J.-J. Toulmé, S. Litvak. Modified (PNA, 2’O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription. Nucleic Acids Res 1998; 26, 5492-5500.

Boulmé F, Freund F, Litvak S. Initiation of in vitro reverse transcription from tRNALys3 on HIV-1 and HIV-2 RNAs by both type 1 and type 2 reverse transcriptases. FEBS Letters 1998; 430, 165-170.

Dufour E, El Dirani-Diab R, Boulmé F, Fournier et al. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1: interactions with primer tRNALys3, initiation of cDNA synthesis and effect of inhibitors. Eur J Biochem 1998; 251, 487-495.

Boulmé F, Perälä-Heape M, Sarih-Cottin L, Litvak S. Specific inhibition of in vitro reverse transcription using antisense oligonucleotides targeted to the TAR regions of HIV-1 and HIV-2. Biochim Biophys Acta 1997; 1351, 249-255.

Dermatologie

Preibisz L, Boulmé F, Lorenc ZP. Barbed polydioxanone sutures for face recountouring: six-month safety and effectiveness data supported by objective markerless tracking analysis. Aesthet Surg J 2022; 42(1): NP41-NP54.

Neurologie

Likar R, Aroyo I, Bangert K, Degen B et al. Management of swallowing disorders in ICU patients – a multinational expert opinion. J Crit Care 2023; epub ahead a print (aide à la rédaction).

Blakemore C, Hunter J, Basu B. Rapid swallow improvement following pharyngeal electrical stimulation in a COVID-19 patient with long-term severe neurogenic dysphagia: a case report. JRM-CC 2021; 4: 1000073 (aide à la rédaction).

Beirer S, Grisold W, Dreisbach J. Therapy-resistant dysphagia successfully treated using pharyngeal electrical stimulation in a patient with the pharyngeal-cervical-brachial variant of the Guillain-Barré syndrome. eNeurologicalSci 2020; 20: 100255 (aide à la rédaction).

Rhumatologie

Roux C, Cortet B, Chapurlat R, Lévy-Weil FE et al. Management of bone fragility in patients with rheumatoid arthritis in France: An analysis of a national health insurance claims database. Joint Bone Spine 2022; 89(4): 105340 (aide à la rédaction).

Diabète

Skovlund SE, Renza S, Laurent J, Cerletti P. Identification of core outcome domains and design of a survey questionnaire to evaluate impacts of digital health solutions that matter to people with diabetes. J of Diabetes Sci and Technol 2023; 19322968231179740 (aide à la rédaction).

Hématologie

*Première co-auteur

Boulmé F. Therapie précoce de polycythemia vera, y compris chez les patients présentant un faible risque. Congress report ÖHEM 2022. memo InHaematology special issue by Springer-Verlag GmbH, en allemand.

Boulmé F. Myeloproliferative neoplasms/polycythemia Vera: perspectives in modern interferon therapy. Congress report e-IHEM 2021. memo InHaematology special issue, by Springer-Verlag GmbH.

Boulmé F. Diagnostic de la mastocytose. Meeting d’experts, Mai 2021, en allemand.

Boulmé F. FMC: La maladie des cellules falciformes. Die Punkte:On, MedMedia Austria, Mai 2021, en allemand.

Boulmé F. FMC: Diagnostique de la mastocytose systémique. Die Punkte:On, Medmedia Austria, Avril 2021, en allemand (https://medonline.at/fortbildung/dfp-e-learning/clinicum-onko/10057611/real-world-evidence/)

Pradet-Balade B, Leberbauer C, Schweifer N, Boulmé F. Massive translational repression of gene expression during mouse erythroid differentiation. Biochim Biophys Acta 2010; 1799, 630-641.

Leberbauer C, Boulmé *F , Unfried G, Huber J et al. Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors. Blood 2005; 105, 85-94.

Joosten M, Blazquez-Domingo M, Lindeboom F, Boulmé *F et al. Translational control of putative proto-oncogene Nm23-M2 by cytokines via phosphoinositide 3-kinase signaling. J Biol Chem 2004; 279, 38169-38176.

Dolznig H, Boulmé F, StanglK, Deiner EM et al. Establishment of normal, terminally differentiating mouse erythroid progenitors: molecular characterization by cDNA arrays. FASEB J 2001; 15, 1442-1444.

Contrôle de la traduction

Pradet-Balade, Boulmé F, Beug H, Müllner EW et al. Translation control: bridging the gap between genomics and proteomics? Trends Biochem Sci 2001; 26, 225-229.

Pradet-Balade B, Boulmé F, Müllner EW, Garcia-Sanz JA. Reliability of mRNA profiling: verification for samples with different complexities. Biotechniques 2001; 30, 1352-1357.